CD316/IGSF8 Protein, Mouse (HEK293, His)

The CD316/IGSF8 protein plays a key role in functions related to CD81 and CD9, affecting oocyte fertilization and may affect HCV function. It regulates keratinocyte proliferation, acts as a negative regulator of cell motility, and binds to CD82 to inhibit prostate cancer cell migration. CD316/IGSF8 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD316/IGSF8 protein, expressed by HEK293 , with C-His labeled tag.

The CD316/IGSF8 protein appears to play a pivotal role in a variety of functions attributed to CD81 and CD9, such as oocyte fertilization and potential involvement in hepatitis C virus function. Additionally, it is implicated in regulating the proliferation and differentiation of keratinocytes and may act as a negative regulator of cell motility, suppressing T-cell mobility in coordination with CD81, associating with CD82 to suppress prostate cancer cell migration, and regulating epidermoid cell reaggregation and motility on laminin-5 with CD9 and CD81 as crucial linkers. CD316/IGSF8 might also contribute to integrin-dependent morphology and motility functions, participating in the regulation of neurite outgrowth and the maintenance of the neural network in the adult brain. Interactions with CD82, CD9/tetraspanin-29, integrin alpha-3/beta-1, and integrin alpha-4/beta-1 are suggested, with additional participation in a complex composed of CD9, PTGFRN, and CD81. Furthermore, direct interaction with CD81/tetraspanin-28 is noted, emphasizing the intricate network of associations that define the diverse roles of CD316/IGSF8 in cellular processes.

Measured by its binding ability in a functional ELISA. Immobilized Mouse CD316 at 1 µg/mL can bind Biotinylated Mouse CD81. The ED₅₀

• 
  Measured by its binding ability in a functional ELISA. Immobilized Mouse CD316 at 1 µg/mL can bind Biotinylated Mouse CD81. The ED₅₀ for this effect is 1.152 μg/mL.

Mouse

HEK293

C-10*His

Q8R366 (R26-T577)

140559  [NCBI]

RQVHVPRGPLYRVAGTAVSISCNVSDYEGPAQQDFEWFMYRPEAPATSLGIVSTKDSQFSYAVFGPRVASGDLQVQRLKGDSVVLKIARLQAQDSGFYECYTPSTDTQYLGNYSAKVELRVLPDELQVSAAPPGPRGRQAATSPSRLTVHEGQELALGCLAQTKTKKHTHLSVSFGRAIPEAPVGRATLQEVVGLRSDMAVEAGAPYAERLASGELRLSKEGTDRYRMVVGGAQAGDSGTYHCTAAEWIQDPDGSWVQVAEKRAVLAHVDVQTLSSQLAVTVGPGERRIGPGEPLELLCNVSGALPPPGRHAAYSVGWEMAPAGAPGPGRLVAQLDTEGIGSLGPGYEDRHIAMEKVASRTYRLRLEAARPADAGTYRCLAKAYVRGSGTRLREAASARSRPLPVHVREEGVVLEAVAWLAGGTVYRGETASLLCNISVRGGPPGLRLAASWWVERPEEGELSSGPAQLVGGVGQDGVAELGVRPGGGPVSVELVGPRSHRLRLHGLGPEDEGIYHCAPSAWVQHADYSWYQAGSARSGPVTVYPYTHAVDT

Approximately 65-77 kDa due to the glycosylation.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.